Careers in Israel
Careers in USA
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Annual and Quarterly Reports
Therapeutic product discovery
In the information age
The next wave in immuno-oncology
Nov 07, 2017
Compugen Reports Third Quarter 2017 Results
Nov 06, 2017
Compugen to Initiate Manufacturing of COM902, its Lead anti-TIGIT Monoclonal Antibody
Our optimized process for predictive discovery of novel drug targets
Discovery & development of first-in-class monoclonal antibody therapeutics
Compugen, FROM CODE TO CURE
CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
Jan 22, 2018
The Precision Medicine World Conference 2018 Silicon Valley
Jan 16, 2018
2018 Keystone Symposia – T Cell Dysfunction, Cancer and Infection (A3)
Nov 10, 2017
32nd Annual Meeting of the Society for Immunotherapy of Cancer
In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...
Click here for more info about partnering with Compugen